Horizon Therapeutics announced it plans to pursue the development of HZN-825, a potential therapy for diffuse cutaneous systemic sclerosis (dcSSc) that it gained in acquiring Curzion Pharmaceuticals. Horizon plans to conduct a study this year to investigate the pharmacological profile of HZN-825, previously known as CZN001. Company leaders…
First, the bad news: If you’re one of the 30 million or so Americans with a rare disease, you probably have lower immunity to the novel coronavirus than most people. Now, the good news: You already know how to face loneliness and adversity — qualities that make you far stronger…
Emerald Health Pharmaceuticals has launched a clinical trial evaluating EHP-101, its investigational cannabidiol-derived therapy, in adults with diffuse cutaneous systemic sclerosis (dcSSc). “This is our first Phase 2 clinical study, which is another important milestone for our lead product candidate,” Joachim Schupp, MD, Emerald Health’s chief…
The active ingredient in EHP-101 — known as VCE-004.8, derived from synthetic cannabidiol — is not classified as a controlled substance under Canada’s Controlled Drug and Substance Act (CDSA), the potential treatment’s developer, Emerald Health Pharmaceuticals, reported. VCE-004.8 is a non-reactive, non-psychotropic synthetic compound derived from cannabidiol, or CBD,…
The Living Rare, Living Stronger Patient and Family Forum, originally set for May 14–16 in Cleveland, Ohio, has been postponed until July 18–20 because of the coronavirus disease COVID-19 pandemic. The event’s sponsor, the National Organization for Rare Disorders (NORD),…
Even with the coronavirus pandemic ravaging Europe and much of the world, patient advocate Lucia Monaco, PhD, of Italy remains confident that the Paris-based nonprofit she chairs will see the approval of 1,000 new rare disease therapies by 2027. That group, the International Rare Diseases Research Consortium (IRDiRC) —…
Levels of a subtype of immune B-cells in the blood are increased in some people with scleroderma and associated with lower respiratory function, higher blood pressure in the lungs, and more kidney damage, a study reports. The study, “CD21-low B cells in systemic…
Using vitamin E, pentoxifylline, and the TheraBite Jaw Motion Rehabilitation System may help reduce trismus — commonly called lockjaw — in people with scleroderma, a study in two patients suggests. The research, “Dental management of scleroderma patients using pentoxifylline plus vitamin E with and…
Emerald Health Pharmaceuticals (EHP), the company developing the synthetic cannabis-derived EHP-101 as a treatment for scleroderma, has been granted six patents related to 25 new molecules derived from cannabidiol (CBD) and cannabigerol (CBG). The new patents were granted in Japan, Israel, Australia, and Russia. Both CBD…
Higher-than-normal blood levels of squamous cell carcinoma antigen 1 (SCCA1), a pro-fibrotic protein, are associated with a greater risk of interstitial lung disease (ILD) among people with systemic sclerosis (SSc-ILD), a study suggests. This finding points to SCCA1 blood levels as a potential biomarker for early detection of SSc-ILD,…
Get regular updates to your inbox.